Semaglutide gummiesib lub tswv yim khoom lag luam uas nthuav tawm GLP nrov-1 receptor agonist tshuaj nyob rau hauv daim ntawv tshiab ntawm qhov ncauj lozenge. Nws encapsulates lub active ingredient ntawm semaglutide, uas yog Ameslikas muab los ntawm kev txhaj tshuaj, nyob rau hauv ib tug chewable, feem ntau yog txiv hmab txiv ntoo-flavored gelatinous khoom qab zib. Lub hom phiaj yog los xyaum nws cov teebmeem tseem ceeb ntawm kev ua kom qab los noj mov, ncua kev ua pa ntawm plab, thiab tswj cov ntshav qab zib los ntawm kev zom txhua hnub. Qhov kev tsim qauv no ncaj qha rau cov neeg siv khoom uas ntshai koob lossis nrhiav kev yooj yim, hloov pauv cov kev siv tshuaj kho mob hnyav rau hauv kev noj qab haus huv ntau dua thiab zoo phooj ywg txhua hnub. Txawm li cas los xij, nws yuav tsum tau hais qhia tias tam sim no tsis muaj cov khoom lag luam raug pom zoo rau kev ua lag luam los ntawm cov koom haum tswj hwm tshuaj (xws li FDA). Ib qho "semaglutide gum" thov kom muaj qhov sib npaug ntawm cov khoom noj uas tsis tau lees paub, nws qhov kev huv huv, qhov tseeb ntawm koob tshuaj, thiab kev nyab xeeb yog cov lus nug, thiab tsis tuaj yeem hloov cov tshuaj noj uas tau txheeb xyuas los ntawm kev sim tshuaj nruj heev. Ua ntej siv, nws yog ib qho tseem ceeb uas yuav tau sab laj nrog kws kho mob kom tsis txhob muaj kev phom sij rau kev noj qab haus huv.
Peb Cov Khoom
Semaglutide COA
Semaglutide, raws li GLP-1 receptor agonist, tau pom tias muaj txiaj ntsig zoo hauv kev kho mob ntshav qab zib thiab tswj qhov hnyav. Cov txheej txheem tshuaj ntsuam xyuas rau nws qhov ncauj formulation (xws li cov ntsiav tshuaj chewable los yog cov ntawv qab zib-coated, txawm hais tias daim ntawv tseem ceeb tam sim no yog cov ntsiav tshuaj,zoo li semaglutide gummies) yuav tsum tau coj mus rau hauv tus account cov yam ntxwv ntawm cov tshuaj peptide thiab cov complexity ntawm formulation formulation. Cov nram qab no systematically elaborates lub analytical lub tswv yim rau Semaglutide qhov ncauj formulations los ntawm plaub qhov ntev: analytical txheej txheem xaiv, tseem ceeb parameter tswj, pre- kho optimization, thiab txoj kev validation.
Kev Tshawb Fawb Kev Xaiv: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) raws li cov tub ntxhais kawm
Semaglutide, ib qho 31-amino acid polypeptide tshuaj, muaj qhov hnyav molecular ntawm 4113.6 Da thiab ntau yam metabolites. Cov txheej txheem tshuaj tiv thaiv kab mob ib txwm muaj (xws li ELISA) yog qhov cuam tshuam los ntawm cov kab mob lom, thaum cov tshuaj tiv thaiv kab mob isotope tsis tuaj yeem paub qhov txawv ntawm cov niam txiv sib xyaw los ntawm cov metabolites. LC-MS/MS, nrog rau nws cov rhiab heev (ntaus tau ntawm ng/mL theem), kev xaiv siab (los ntawm ntau-kev tshuaj xyuas hom kom tshem tawm kev cuam tshuam), thiab muaj peev xwm nkag siab, tau dhau los ua tus qauv kub rau hauv vitro thiab hauv vivo tsom xam ntawm semaglutide. Piv txwv li, LC-MS/MS txoj kev tsim los ntawm Longchuan Biotechnology, los ntawm kev kho ua ntej - kho nrog ib qho ion- pauv khoom-theem rho tawm kem ua ke nrog reversed-theem chromatography, tuaj yeem ua tiav qhov ntau npaum li cas ntawm semaglutide hauv plasma 5 / 0. tus nqi ntawm 70% -80%, thiab cov nyhuv matrix tswj nyob rau hauv 0.93-1.1, ua tau raws li qhov yuav tsum tau ntawm kev tshuaj ntsuam xyuas cov tshuaj sib xws.
Key Parameter Control: Qhov tseem ceeb sib npaug rau Molecular Nyhav thiab Impurity Analysis
Lub synthesis ntawm semaglutide koom nrog semi{0}}recombinant txoj kev, suav nrog precursor molecule qhia, lysine sab saw hloov, thiab N-terminal amino acid coupling. Txhua kauj ruam yuav qhia impurities. Matrix-pab laser desorption ionization lub sij hawm- ntawm- dav hlau huab hwm coj spectrometry (MALDI-TOF MS) tau dhau los ua txoj kev nyiam rau kev tswj cov khoom lag luam nruab nrab thiab zaum kawg vim nws qhov muag ionization yam ntxwv (tsuas yog tsim ib qho kev them nqi peaks), kaum ntau qhov kev soj ntsuam ceev (nrog rau ntau pua txhiab tons) (5-10 vib nas this ib qho piv txwv). Piv txwv li, los ntawm kev siv MALDI-8030 benchtop mass spectrometer, cov poov xab recombinant qhia ntawm GLP-1 analog precursor molecule pom lub ntsiab ncov ntawm m / z 3176.23, uas yog raws li qhov theoretical tus nqi ntawm 3176.52, thiab tsis pom muaj impurities pom tseeb; thaum qhov sib txuas nruab nrab tau pom ob lub peaks ntawm m / z 3892.54 thiab 4114.66, sib haum rau cov khoom sib txuas tsis tiav thiab lub hom phiaj molecule feem, qhia tias cov kev sib txuas yuav tsum tau ua kom zoo. Hauv kev tsim cov khoom kawg, ntxiv rau kev kuaj pom [M + H] + (m / z 4114.38), ntau qhov kev them nqi siab xws li [M+2H]2+ (m / z 2057.88) thiab [2M + H] + (m / z 8228.42) kuj raug pom zoo los ntawm kev faib tawm, thiab qhov kev xav tau ntawm molecules. algorithms.
Ua ntej-kev kho kom zoo dua: Hais txog cov teeb meem tshwj xeeb ntawm cov qauv ntawm qhov ncauj
Qhov ncauj semaglutide yuav tsum tau kov yeej ob qho teeb meem loj: degradation los ntawm gastric acid thiab enzymatic hydrolysis nyob rau hauv txoj hnyuv. Nws cov formulations feem ntau siv kev nkag mus rau -txhim kho cov tswv yim (xws li co-formulation nrog SNAC cab kuj) los yog nanocrystal technology los txhim kho bioavailability. Thaum lub sij hawm kev soj ntsuam, tshwj xeeb ua ntej- txoj kev kho mob yuav tsum tau tsim rau formulation excipients (xws li microcrystalline cellulose, cross-txuas carboxymethyl cellulose sodium). Rau cov chewable ntsiav tshuaj los yog cov khoom qab zib mos, cov tshuaj yuav tsum tau muab rho tawm thiab tso tawm los ntawm vortex oscillation los yog ultrasonic pab ua ntej. Tom qab ntawd, ib qho sib xyaw-hom khoom- theem rho tawm kem (xws li MCX kem) yuav tsum tau siv los khaws cov peptides thiab polar impurities ib txhij. Thaum kawg, cov kuab tshuaj organic (xws li acetone-acid tov tov) yuav tsum tau siv rau elution. Rau cov formulations uas muaj siab - qab zib excipients, ib kauj ruam los nag cov protein (xws li ntxiv ib qho acetone-methanol tov tov rau precipitate proteins) yuav tsum tau ntxiv kom tsis txhob muaj matrix cuam tshuam.
Method validation: Kev ntsuam xyuas zoo raws li ICH Cov Lus Qhia
Txoj kev tshuaj ntsuam xyuas yuav tsum tau ua tiav qhov kev lees paub raws li qhov tshwj xeeb, linearity, precision, raug, rov qab tus nqi, cov nyhuv matrix, thiab stability. Piv txwv li, cov kab tawm yuav tsum npog qhov xav tau ntau yam (piv txwv li, 5 - 500 ng / mL), nrog rau kev sib raug zoo coefficient R² Ntau dua lossis sib npaug rau 0.99; qhov intra-hnub/hnub-rau-hnub precision (RSD%) yuav tsum tsawg dua lossis sib npaug li 15%; qhov tseeb (RE%) yuav tsum nyob rau hauv ± 15%; lub khov -thaw stability (xws li, tom qab khov ntawm -80℃rau 3 cycles) yuav tsum muaj tus nqi rov qab ntau dua los yog sib npaug rau 85%. Tsis tas li ntawd, qhov cuam tshuam ntawm qhov chaw cia sib txawv (xws li luv-lub sijhawm txias hauv chav tsev thiab lub tub yees ntev ntev) ntawm kev ruaj ntseg ntawm cov tshuaj yuav tsum raug soj ntsuam kom ntseeg tau tias muaj kev ntseeg siab ntawm cov txiaj ntsig kev soj ntsuam.
|
|
|
|
Kev tsom xam ntawm qhov ncauj formulation ntawm semaglutide yuav tsum ua raws li LC-MS/MS ua lub hauv paus, ua ke nrog kev soj ntsuam ceev ceev ntawm MALDI-TOF MS. Cov kauj ruam ua ntej - kev kho mob yuav tsum tau ua kom zoo raws li cov yam ntxwv ntawm kev tsim, thiab txoj kev siv tau yuav tsum tau ua nruj me ntsis raws li ICH cov lus qhia. Nyob rau hauv lub neej yav tom ntej, nrog rau kev ua txhaum ntawm kev xa xov hauv qhov ncauj ntawm cov tshuaj peptide, cov kev tshuaj ntsuam xyuas yuav tsum tau hloov mus ntxiv rau cov kev xav tau ntawm cov qauv tshiab (xws li microspheres thiab liposomes), muab kev txhawb nqa ntau dua rau kev tshawb fawb tshuaj thiab kev siv tshuaj kho mob.
Tus naj npawb ntawm cov neeg mob ntshav qab zib thiab rog rog thoob ntiaj teb tau nce zuj zus, dhau los ua tus tsav tsheb loj hlob rau Semaglutide Gummies. Raws li kev txheeb cais, tus naj npawb ntawm cov neeg mob ntshav qab zib hauv Suav teb tau nce mus txog 141 lab hauv 2021, thiab nws xav tias yuav nce mus rau 164 lab los ntawm 2030. Nyob rau tib lub sijhawm, cov neeg rog rog (BMI> 27) hauv Suav teb xav tias yuav ncav cuag 200{13}}250 lab, suav nrog kev tswj hwm qhov hnyav tshaj plaws hauv ntiaj teb. Semaglutide, raws li GLP-1 receptor agonist, tau raug kuaj pom tias muaj cov nyhuv hypoglycemic thiab poob phaus. Daim ntawv cov khoom qab zib muag tuaj yeem txhim kho cov neeg mob ua raws li kev npog qhov iab ntawm cov tshuaj thiab txhim kho kev yooj yim ntawm kev tswj hwm, tshwj xeeb tshaj yog nyiam cov neeg ntshai ntawm kev txhaj tshuaj lossis nqos ntsiav tshuaj. Piv txwv li, Eden Lub Tuam Txhab Semaglutide cov khoom qab zib muag tau raug nqi hauv pob khoom txhua hli ($246 - $296), tsom rau cov neeg siv khoom lag luam siab thiab ua tau raws li cov kev xav tau ntawm cov neeg siv khoom uas muaj kev xav tau siab rau kev yooj yim.
|
|
|
Cov tshuaj ntawm qhov ncauj Semaglutide tso siab rau kev nqus tau zoo (xws li SNAC) los txhim kho kev ua haujlwm ntawm lub plab zom mov, tab sis qhov bioavailability tseem qis (tsuas yog 0.8%). Kev tsim cov khoom qab zib mos, los ntawm kev tsim cov thev naus laus zis tshiab xws li nano-cov khoom siv lead ua liposomes, tuaj yeem txhim kho kev ruaj ntseg thiab kev nqus ntawm cov tshuaj. Piv txwv li, ib lub tuam txhab thov tias nws cov khoom qab zib muag tau txo qis degradation los ntawm pepsin los ntawm cov txheej txheem tshwj xeeb, tab sis nws yuav tsum tau muab sau tseg tias cov khoom no tseem tsis tau muaj kev tswj xyuas nruj heev los ntawm FDA, thiab nws cov kev ua tau zoo thiab kev nyab xeeb tseem xav tau loj - ntsuas kev soj ntsuam kuaj xyuas. Yog tias cov cuab yeej ua tiav, cov khoom qab zib muag muag yuav tsum txo tus nqi ntawm cov tshuaj ib zaug thiab nthuav dav kev lag luam.
Txawm hais tias Semaglutide yog ib qho piv txwv hauv GLP-1 daim teb, nws ntsib ob txoj kev sib tw: Ntawm ib sab, cov tshuaj xws li Tirzepatide (GIP / GLP-1 dual receptor agonist) ua tau zoo dua hauv kev poob phaus thiab kev txhim kho metabolic (raws li qhia hauv SURMOUNT-5 txoj kev tshawb fawb, qhov nruab nrab ntawm 20% ntawm qhov hnyav ntawm Semaglutide); ntawm qhov tod tes, qhov ncauj me me molecule GLP-1 agonists (xws li Orforglipron) tuaj yeem txeeb khw nrog cov nqi qis dua. Qhov sib txawv ntawm qhov zoo ntawm cov khoom qab zib mos yog nyob rau hauv kev tsim kho tshiab ntawm daim ntawv ntau npaum, tab sis nws yuav tsum tau ua pov thawj los ntawm lub taub hau - mus rau lub taub hau kev sim uas nws cov kev ua tau zoo tsis qis dua cov tshuaj uas twb muaj lawm. Tsis tas li ntawd, cov tshuaj peptide tau tsim los ntawm ntau lub hom phiaj sib koom ua ke, xws li triple agonist UTG-4 ntawm GLP-1 / GCGR / GIP, uas qhia tau hais tias muaj zog dua hauv kev sim tsiaj. Yog tias cov khoom qab zib mos tuaj yeem sib xyaw ua ke ntau lub hom phiaj yav tom ntej, nws tuaj yeem qhib qhov chaw lag luam tshiab.
Cov tshuaj txhaj tshuaj ntawm semaglutide (xws li Wegovy) raug txwv hauv qee lub khw vim nws tus nqi siab (ib hlis tus nqi kwv yees li $ 1000), thaum daim ntawv gummy, yog tias nws tuaj yeem txo tus nqi los ntawm kev ua kom zoo dua, yuav tau txais kev txhawb nqa ntau dua los ntawm cov chaw them nyiaj. Tsis tas li ntawd, cov cai tswj kev pov hwm kho mob rau kev rog rog hauv ntau lub tebchaws tau maj mam txhim kho. Piv txwv li, Asmeskas kev tuav pov hwm kho mob tau suav nrog Wegovy hauv kev them nyiaj rov qab rau qee qhov kev kho mob rog, thiab Tuam Tshoj tseem tab tom tshawb nrhiav kev suav nrog GLP-1 cov tshuaj hauv kev tswj hwm cov kab mob tshwj xeeb. Daim ntawv gummy yuav tsum tau ua pov thawj nws cov nqi-zoo los ntawm cov ntaub ntawv kho mob los pab txhawb nws nkag mus rau hauv kev pov hwm kho mob.
|
|
|
|
Cov cim qhia ntawm semaglutide tau nthuav dav los ntawm cov ntshav qab zib thiab rog rog mus rau thaj chaw xws li kev pheej hmoo ntawm cov hlab plawv, kab mob raum ntev, metabolic dysfunction -txog steatohepatitis (MASH), thiab lwm yam. Piv txwv li, SELECT txoj kev tshawb fawb pom tau tias nws tuaj yeem txo qis kev pheej hmoo ntawm cov hlab plawv los ntawm 20% ntawm cov neeg mob ob leeg. Yog hais tias cov ntsiav tshuaj chewable formulation tuaj yeem txhim kho cov neeg mob lub sijhawm ntev - kev ua raws li cov tshuaj noj los ntawm kev yooj yim, nws tuaj yeem ua kom nws txoj hauj lwm hauv kev tswj kab mob ntev. Tsis tas li ntawd, yog tias kev tshawb fawb txog cov kab mob neurodegenerative xws li Alzheimer's kab mob (xws li GLP-1 receptor agonists txhim kho microglial cell function) ua tiav, cov ntsiav tshuaj chewable formulation yuav yog ib qho kev xaiv tshiab rau kev kho mob.
FAQ
1. Nws muaj feem cuam tshuam li cas rau kev pov tseg cov khoom siv kho mob?
Yog tias nws muaj cov khoom xyaw nquag, nws yuav raug cais raws li cov tshuaj pov tseg. Txawm li cas los xij, raws li cov neeg siv khoom lag luam nrog "khoom qab zib" zoo li, nws txoj kev ntim khoom thiab kev siv yuav ua rau cov neeg siv khoom yuam kev kom muab pov tseg raws li cov khib nyiab tsis tu ncua, ua rau cov khoom siv tshuaj nquag nkag mus rau hauv tsev pov tseg. Qhov no tuaj yeem ua rau muaj kev cuam tshuam tsis paub txog cov kab mob hauv ib puag ncig lossis tsiaj qus, uas tsis muaj nyob hauv cov tshuaj txhaj tshuaj.
2. Rau cov khoom qab zib muag muag no yog "cov khoom noj khoom haus", cov qauv kev tsim khoom puas tuaj yeem ua tau raws li cov kev cai huv huv rau cov tshuaj peptide?
Feem ntau tsis yog. Kev tsim cov tshuaj peptide tsis tu ncua yuav tsum tau ua nyob rau hauv ib puag ncig huv si rau kev npaj lom neeg los tiv thaiv kev kis kab mob microbial thiab hla- cov tshuaj tiv thaiv. Txawm li cas los xij, cov qauv tsim khoom ntawm cov khoom noj khoom haus zoo tib yam khoom qab zib yog qis dua qhov no, thiab cov khoom yuav muaj cov kab mob los yog impurities, qhia txog kev pheej hmoo ntxiv.
3. Yuav ua li cas cov khoom muaj nyob rau hauv Semaglutide Gummies nyob ruaj khov thiab zoo absorbed nyob rau hauv lub siab acidic ib puag ncig ntawm lub plab?
Qhov no yog precisely lub tseem ceeb technical kev sib tw. Qhov kev txhim khu kev qha patented qhov ncauj semaglutide tso siab rau qhov tshwj xeeb absorption enhancer (SNAC) thev naus laus zis, uas ua rau ib ntus nce pH tus nqi hauv zos thiab txhawb nqa transcellular absorption. Ordinary gummy candies tsis muaj tus mob no, yog li feem ntau "cov khoom qab zib mos" cov khoom lag luam hauv khw yuav luag tsis tuaj yeem ua tiav cov tshuaj - qib bioavailability, thiab lawv cov txiaj ntsig tau thov yog nug.
Cim npe nrov: Tuam Tshoj semaglutide gummies manufacturers, lwm tus neeg
